Chemotherapy for advanced cancers.
| Autor: | Rajagopal PS; Columbia University College of Physicians and Surgeons, 630 W. 168th St., New York, NY 10032, USA., Nipp RD; Dana-Farber Cancer Institute, Boston, MA, 450, Brookline Ave, Boston, MA 02215, USA., Selvaggi KJ; Dana-Farber Cancer Institute, Boston, MA, 450 Brookline Ave, Boston, MA 02215, USA. Kathy_Selvaggi@DFCI.harvard.edu. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Annals of palliative medicine [Ann Palliat Med] 2014 Jul; Vol. 3 (3), pp. 203-28. |
| DOI: | 10.3978/j.issn.2224-5820.2014.06.02 |
| Abstrakt: | The decision to treat with chemotherapy in advanced cancers is a complex process that requires oncologists to weigh the indications and benefits. Treatment of patients with advanced cancer is typically multidimensional and should ideally include oncologists in coordination with palliative care specialists. When the intent of chemotherapy for patients with advanced neoplasms is no longer curative, palliative care can and should be delivered simultaneously with antineoplastic agents. Often, chemotherapy for advanced cancers is delivered in an attempt to palliate symptoms, and therefore improve quality of life (QOL). The role of palliative chemotherapy should be continually reevaluated throughout the trajectory of the patient's illness. When chemotherapy is no longer controlling the disease or helping symptoms, the role of chemotherapy should be reconsidered. This review aims to provide a foundation for discussions about treatment of patients with advanced malignancies. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|